remibrutinib (Rhapsido)
Jump to navigation
Jump to search
Indications
- chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment (FDA-approved Sept 2025)
Mechanism of action
- selective Bruton tyrosine kinase (BTK) inhibitor
- blocks BTK-mediated degranulation of mast cells & autoantibody production by B cells[1]
References
- ↑ 1.0 1.1 Metz M, et al. Remibrutinib in Chronic Spontaneous Urticaria. N Engl J Med. 2025. 392:984-994 March 5 PMID: https://pubmed.ncbi.nlm.nih.gov/40043237 Clinical Trial. https://www.nejm.org/doi/10.1056/NEJMoa2408792
- ↑ Chu AWL, Oykhman P, Chu X et al Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis. J Allergy Clin Immunol. 2025 Jul 11:S0091-6749(25)00646-3. PMID: https://pubmed.ncbi.nlm.nih.gov/40663028 Free article. https://www.jacionline.org/article/S0091-6749(25)00646-3/fulltext